Healthcare products company CCA Industries Inc (OTC:CAWW) disclosed on Monday that its income amounted to USD349,320 for the second quarter ended 31 May 2019.
This marks an improvement when compared with a loss of USD292,320 for the same period in fiscal 2018.
Revenues of USD5.458m were generated for the three months ended 31 May 2019,up over revenues of USD4.225m for the comparable period in fiscal 2018.
EBITDA of USD574,176 were recorded for the second quarter ended 31 May 2019, a rise from EBITDA of USD231,136 for the corresponding period in fiscal 2018.
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline